Streamex Corp 8-K, filed Apr 28, 2023
Streamex Corp. (STEX)
About this 8-K
Streamex Corp filed this 8-K on April 28, 2023.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) | Identification No.) |
| | | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
|
N/A (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| | | The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
BioSig Technologies, Inc. (the “Company”) intends, from time to time, to present, utilize, and/or distribute to the investment community and utilize at various industry and other conferences, a slide presentation and corporate summary, which are attached hereto as Exhibits 99.1 and 99.2, respectively. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1 and 99.2.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
|
99.1 |
Corporate Presentation dated April 2023 (furnished herewith pursuant to Item 7.01) |
|
| 99.2 | Corporate Summary dated April 2023 (furnished herewith pursuant to Item 7.01) | |
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BIOSIG TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
Date: April 28, 2023 |
|
|
|
|
|
By: |
/s/ Kenneth L. Londoner |
|
|
|
|
Name: Kenneth L. Londoner |
|
|
|
|
Title: Executive Chairman |
|
Exhibit 99.1
This presentation contains forward-looking statements including statements that address activities, events, or developments that BioSig expects, believes, or anticipates will or may occur in the future, such as predictions of financial performance, approvals, and launches by BioSig of new products, market acceptance of BioSig’s products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig’s experience and perception of current conditions, trends, expected future developments, and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig’s control.
These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig’s products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in BioSig’s SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions, and share price volatility.
BioSigdoes not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Reimagining what’s possible in cardiac care
We are a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms.
By leveraging a first-of-its-kind combination of hardware and software, our technology delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines.
Growing into an expanding global market
$1.6B Total global addressable market
14.4 million Americans suffer from cardiac arrhythmias
Atrial Fibrillation is the most common arrhythmia affecting: ~6.1 million people in the U.S. and growing ~33.5 million people worldwide
Catheter ablation is fast becoming a first-line therapy
Global ablation procedures: ~1.5 million in 2022 ~8.4% CAGR
Complex ablation procedures: ~13.5% projected CAGR
EP labs are growing to meet demand
Estimated: 3,425 EP labs in U.S. 3,915 EP labs OUS
Data source: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion By 2026. Definitive Healthcare, U.S. News & World Report, Newsweek, and BioSig estimates
Presenting the PURE EP™ Platform
Poised to disrupt the field of electrophysiology, PURE EPTM delivers unprecedented intracardiac signal purity that pushes the boundaries of cardiac arrhythmia identification.
PURE EPTM offers one-of-a-kind algorithms, configurable features, and novel applications not found on any other platform—and there’s more in the pipeline.
Saving procedural time and improving workflow efficiency, PURE EPTM eliminates unnecessary inefficiencies to support cost savings.
Supporting our clinical profile with data and economic value
Signal Clarity & Relevance1
In a multi-center, randomized prospective study, PURE EP™signals were compared to conventional recording and mapping systems signals: 75% of PURE EP™ signals rated superior in quality 83% of the time, physicians were more confident in differentiating signal components with PURE EP™ 73% of the time, PURE EP™ produced superior small, fractionated signals of clinical significance
Improved Workflow, Time & Cost Savings2
To determine the difference in procedural times when comparing ablations guided by PURE EP™’s electrocardiogram (EGM) visualization to the conventional system: PURE EP™led to a mean procedure time reduction of: 11.3 minutes Given that the mean cost of operating room time is approximately $37 per minute3, PURE EP™ demonstrated potential cost savings of approximately: $418.10 per procedure
1.Al-Ahmad A, Knight B, Tzou W, et al. Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0. study. J Cardiovasc Electrophysiol. 2021;32(11):2915-2922. Epub 2021 Oct 1. DOI: 10.1111/jce.15250
2. Gallinghouse, G. Joseph; Natale, Andrea; Al-Ahmad, Amin; Della Roca, Domenico Giovanni; Jones, Sterling; Firmstone, Samantha; Lewen, Jason. (2022). Time of Redo Atrial Fibrillation Ablation Procedures with PURE EP Recording System for ECG/EGM Visualization: A Randomized Study. Paper presented at APHRS 2022 Singapore: The 15th APHRS Scientific Session [PP-069-2-AF (55)]. Identifier: NCT04964440.
3. Chudzik, R., Distel, D., Stoneman, L., Thording, L. Why Hospital Leaders Should Look to Cardiology for Sustained Future Reprocessing Savings. (2018, April 25). Innovative Health. https://blog.innovative-health.com/blog.
Integrating into EP labs for improved efficiency
PURE EP™ delivers unprecedented clarity of the raw electrical signals of the heart, unburdening physicians from having to parse through interference of outputs from conventional technology–an on-going problem in EP labs.
Accelerating commercialization of the PURE EPTM Platform
Limited market release 1.0 •Selective installations •7 centers •Learning, fixing, improving •First sale 2019-2020
Limited market release 2.0 •Expansion –17 centers •Clinical trial •Peer-reviewed publication 2021-2022
National commercial expansion •National sales team expansion •GPO/IDN development 2022
Full market release* •National, full-scale roll out 2023
* Expected Full market release.
Current footprint
“Having high-quality, better signals makes a difference in almost every case. Since we installed the system in our lab, the efficiency in which we operate has significantly improved.”
~Dhanunjaya DJ Lakkireddy, MD
Kansas City Heart Rhythm Institute, Overland Park, KS
Complex AF Case Study Utilizing a New Standard in Signal Processing
Led by strong industry experience
Kenneth L. Londoner, MBA Founder, Chairman, Chief Executive Officer, Director Endicott Management Partners; J & W Seligman & Co.; Visiting Professor, Columbia University
Gray Fleming Chief Commercial Officer St. Jude Medical; Abbott Laboratories
John Sieckaus Chief Operating Officer St. Jude Medical; Abbott Laboratories
Steve Buhaly Chief Financial Officer Qorvo; Longview Fibre; Planar System
Brenda Castrodad VP, Human Resources TissueTech, Inc.; HeartWare Inc.
Maintaining well-protected IP
59 Utility and Design Patents Granted/ Allowed in the Field of Digital Signal Processing
29 Worldwide Fundamental Patents Granted/Allowed
11 Pending Applications in the U.S.
12 Pending Applications in APAC
30 Worldwide Design Patents Granted/Allowed
8 Pending Applications in Europe
As of April 25, 2023. This includes applications/patents exclusively licensed from May Foundation for Medical Education and Research
Why BioSig now?
The solution Solving the critical unmet need for better intracardiac information that may improve success rates of ablation procedures.
First customers are industry leaders World-renowned Medical Centers of Excellence.
Disruptive and novel technology Our technology saves procedural time and improves workflow efficiency in an environment where the technology has not changed meaningfully in 25+ years.
Flexible pricing model Supports recurring revenue and continuous innovation.
Substantial and growing global market Global EP market is growing by 11.2% and expected to reach $16B by 2028.
Fortune 500 commercial team Proven track-record of generating sales growth.
Strong clinical data pipeline Published/ongoing clinical studies supporting commercialization.
Well-protected IP portfolio 59 Worldwide fundamental patents granted/allowed.
*Global Market Insights Inc. March 08, 2022.
Upcoming Events
New Customer announcements* U.S. product acquisitions and expansion of footprint.
Participation at Heart Rhythm 2023 in New Orleans May 19-21The largest gathering of heart rhythm professionals from around the world.
Release of Clinical Data May 2023* Multiple abstracts have been accepted for presentation at Heart Rhythm 2023.
Software rollout Spring 2023, Fall 2023 and 2024* Commitment to continuous feature innovation.
* Expected.
Key References
Optimizing signals in the EP lab Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates and Updates in EP - March 2022. Click here to open
Complex AF case study utilizing a new standard in signal processing Dhanunjay Lakkireddy, MD (Executive Medical Director, Kansas City Heart Rhythm Institute, Overland Park, KS - USA) – January 2022 - 27th Annual International AF Symposium Click here to open
Incorporating advanced intracardiac signal information Into the clinical workflow G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – December 2021 - Click here to open
PURE EP™ - from clinical data to clinical applications Wendy Tzou, MD (University of Colorado Denver, CO.), Andrea Natale, MD and Amin Al-Ahmad, MD (Cardiac electrophysiologists - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Live Roundtable Webinar – Nov. 2021. Click here to open
Evaluation of a novel cardiac signal processing system for electrophysiology procedures: The PURE EP 2.0 Study - Al-Ahmad A, Knight B, Tzou W, et al. - J Cardiovasc Electrophysiol. 2021;32(11):2915-2922. Epub 2021 Oct 1. doi: 10.1111/jce.15250. Click here to open
PURE EP™ - a new standard in signal processing Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – KC HRS 2021 - August 2021. Click here to open
From clinical data to clinical applications Christopher McLeod, MB, ChB (Cardiac electrophysiologist – Mayo Clinic - Jacksonville, FL – USA) – HRS 2021 – Non-CME Satellite Symposium - July 2021 - Click here to open
The evolution of intracardiac signal acquisition and processing in today’s EP lab environment - Interview with Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates & Updates in Electrophysiology - April 2021. - Click here to open
Improved intracardiac signal visualization during cryo and RF procedures Deepak Gaba, MD (Cardiac electrophysiologist – Memorial Hospital, South Bend, IN – USA) - April 2021. shares his views on how the PURE EP™ System can help be more efficient and how high-fidelity signals can improve clinical outcomes - Click here to open
Benefits of the PURE EP™ System in identifying and interpreting low amplitude signals G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – January 2021 - 26th International Annual AF Symposium. Hyperlink to access resources: Click here to open
Further optimizing electrogram signal quality in the EP lab Bradley P. Knight, MD, FACC, FHRS (Professor of Medicine and Director of EP - Northwestern University, Chicago, IL - USA) – January 2021 - Click here to open\
Advanced signal acquisition help drive procedural efficiency and efficacy Raffaele Corbisiero, MD, EPS and Pedram Kazemian, MD (Deborah Heat and Lung Center, Browns Mills, New Jersey – USA) EP Lab Digest – December 2020 - Click here to open
VT in NICM by Pasquale Santangeli, MD, PhD - University of Pennsylvania Health System, Philadelphia, PA – USA – November 2020 Hyperlink to access resources: Click here to open
PURE EP case review on how high-fidelity intracardiac signals can help visualize conduction pathways faster - Andrea Natale, MD, FACC - Austin, TX – USA – September 2020 - Click here to open
ESC 2020: A novel cardiac signal processing system for electrophysiology procedures: early insights from the pure ep 2.0 study - Click here to open
Cardiac signal acquisition and clinical considerations for accurate interpretation Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – June 12, 2020. Click here to open
Cardiac signal acquisition and clinical implications of applying filters Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – July 1, 2020 Click here to open
PURE EP™ is addressing critical unmet needs - frequency bandwidth and linear signal acquisition Dr Venkatachalam’s presentation (Mayo Clinic, Jacksonville, FL - USA) – May 2020 -Stanford Biodesign New Arrhythmia Technologies Retreat - Click here to open
Shaping the future of EP through advanced signal processing and analysis Andrea Natale, MD, FACC (St David’s Medical Center, Austin, TX – USA) and Matthew Dare, CEPS – April 2020 - Click here to open
Contact us
Andy Ballou VP of Investor Relations aballou@biosigtech.com203-409-5444, x133
BioSig Technologies, Inc.55 Greens Farms RoadWestport, CT 06880
www.biosig.com
Exhibit 99.2
| BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. By leveraging a first-of-its-kind combination of hardware and software, BioSig delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The Company operates within the rapidly growing electrophysiology (EP) marketplace—a market projected to reach $16B by 2028 with an 11.2% growth rate.* |
BioSig Technologies, Inc. 55 Greens Farms Road Westport, CT 06680
www.biosigtech.com
info@biosigtech.com
|
|
| BioSig's first product, the PURE EP™ Platform, is an FDA 510(k) cleared non-invasive class II device, that removes the unnecessary distractions, noise, and signal interruptions inherent in traditional approaches to capturing cardiac signals—preserving access to the full-spectrum of raw signal data and delivering clear actionable insights that can be explored for highly-tailored, efficient procedures in the treatment of arrhythmias. |
Kenneth L. Londoner CEO, Co-Founder, Chairman
BioSig Technologies, Inc.
Phone: (203) 409-5444, x133
klondoner@biosigtech.com
|
|
| The PURE EP™ Platform is already an integral part of many well-respected healthcare systems, including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. |
Andrew Ballou Vice President, Investor Relations
BioSig Technologies, Inc.
Phone: (203) 409-5444, x133
aballou@biosigtech.com
|
CORPORATE SUMMARY
*Global Market Insights Inc. March 08, 2022.
KEY GROWTH DRIVERS
Advanced Technology
| ● | While the field of cardiology has advanced in innumerable ways, platforms for capturing cardiac signaling have not kept pace. BioSig is solving the critical unmet need for delivering better cardiac signaling information that can potentially help improve success rates of ablation procedures, which are fast becoming first-line procedures to treat arrhythmias. | ● | The PURE EP™ Platform combines noise-dampening physical hardware with one-of-a-kind algorithms and customizable software features to eliminate distortion and provide vital data analysis and pure cardiac signals that allow for enhanced evaluation and confidence in the treatment of arrhythmias. |
Market Opportunity
| ● |
The global electrophysiology market is expected to exceed US $16B by 2028 and is growing at a compound annual growth rate (CAGR) of 11.2%. |
KOL Support
| ● | The PURE EP™ Platform is in use by many of the nation's leading medical centers and physicians, including Dr. Andrea Natale and Dr. G. Joseph Gallinghouse of Texas Cardiac Arrhythmia Institute; Dr. Dhanunjaya “DJ” Lakkireddy of Kansas City Heart Rhythm Institute, and Oussama Wazni, MD of Cleveland Clinic |
 |
| ● | The Company achieved proof of concept validation through UCLA and has performed numerous preclinical and clinical studies at leading Medical Centers of Excellence. In 2017, the Company inked a 10-year strategic collaboration with Mayo Clinic. More recently, the Company signed a Master Research Agreement with Cleveland Clinic to explore expanded applications for the PURE EP™ Platform. |
| RECENT HIGHLIGHTS | ||||
 |
Signed Purchase Agreement with Bellin Health in Green Bay, Wisconsin |
 |
Announced Multi-System Evaluation Agreement with Cleveland Clinic | |
 |
Signed Purchase Agreement with San Antonio Methodist Hospital |
 |
Surpassed 3,000 procedures | |
 |
Signed Purchase Agreement with Kansas City Rhythm Institute at Overland Park Medical Center |
 |
59 allowed/issued design and utility patents | |
 |
PURE EP™ highlighted in a peer-reviewed case report (JAFIB- EP) |  |
Clinical data acquired by PURE EP™ published in the Journal of Cardiovascular Electrophysiology | |
 |
Signed Master Agreement with Hospital Corporation of America (HCA) |
 |
Selected Plexus Corp. as its manufacturing partner | |
THE PURE EP™ PLATFORM
| A unique combination of proprietary hardware and software, The PURE EP™ Platform removes unnecessary distractions to preserve the value of cardiac signals and delivers clear, actionable insights for today's electrophysiologist. PURE EP™ is demonstrating impact on hospital profitability through innovative feature designs not found in any other platform. |
 |
|
 |
Reduce EP lab noise and artifacts
|
|
|
|
Deliver clean, superior intracardiac signal visualization | |
|
|
Offer customizable, advanced software modularity | |
|
|
Enhance clinical workflow and increase throughput | |
|
|
Empower physicians with actionable insights | |
|
|
Improve clinical decision-making | |
The company's subscription model supports operational expenditure goals by optimizing case-by-case and day-to-day department expenses, removing the burden of ownership and maintenance. With a comprehensive suite of tools and software upgrades, the PURE EP™ Platform can deliver the latest developments in electrophysiology to physicians as they emerge, with the flexibility to add enhancements as desired.
|
A GROWING GLOBAL MARKET
The Cardiac Arrhythmia Epidemic: 14.4M Americans suffer from cardiac arrhythmias.
Two of the most prevalent, complex and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). • AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B. • Ventricular arrhythmias account for approximately 300,000 sudden deaths per year in the United States alone.
Catheter ablation is fast becoming a first-line therapy, driving demand for improved technologies. • Global Ablation Procedure Growth: 8.4% growth rate, from 973,220 in 2017 to 1.45 projected million in 2022. • Complex Ablation Procedures: 440,629 in 2017 to 830,390 in 2022; 13.5% projected growth rate. • Estimated 3,425 EP labs in US • Estimated 3,915 EP labs OUS |
INVESTMENT HIGHLIGHTS | ||
 |
Proven management team and independent Board of Directors | ||
 |
Substantial and growing market | ||
 |
Strong clinical data supports commercialization | ||
 |
Technology solves a critical unmet need, saves procedural time, and improves workflow efficiency | ||
 |
Flexible pricing model supports recurring revenue and continuous innovation | ||
 |
First customers are industry leaders | ||
 |
IP Strategy led by Sherpa Technology and Sterne Kessler Goldstein & Fox—59 allowed/issues patents | ||
 |
Significant Insider Ownership | ||
 |
National purchasing agreement with HCA, Inc. | ||
 |
10-year strategic collaboration with Mayo Clinic | ||
PROVEN TEAM
BioSig is led by a proven management team with significant inside ownership. BioSig has brought together leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions for its Advisory Board, including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.
|
MANAGEMENT AND PAST EXPERIENCE |
Kenneth L. Londoner, MBA Founder, Chairman, Chief Executive Officer, Director Endicott Management Partners; J & W Seligman & Co., Visiting Professor, Columbia University |
Steve Buhaly Chief Financial Officer Qorvo; Longview Fibre; Planar Systems |
|
|
Gray Fleming Chief Commercial Officer St. Jude Medical; Abbott Laboratories |
John Sieckhaus Chief Operating Officer St. Jude Medical; Abbott Laboratories |
||
|
|
|
||
|
Andrew Ballou VP, Investor Relations Janney Montgomery Scott LLC., RBC Capital Markets |
Brenda Castrodad VP, Human Resources TisueTech, Inc., HeartWare Inc. |
||
|
Katie Freshwater VP, Marketing Cardinal Health, Medtronic, Kimberly-Clark Healthcare |
Zachary Koch CCDS, CEPS, Clinical Director Abbott, St. Jude Medical |
|
DIRECTORS |
Donald E. Foley Director Former CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co |
Patrick J. Gallagher, MBA Director Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody |
|
|
|
|
||
|
David Weild IV, MBA Director Current Chairman & CEO; Weild & Co.; Former Vice Chairman: NASDAQ; Former Head of Corporate Finance & Equity Markets: Prudential Securities |
Frederick D. Hrkac Director 30+ years of industry experience including Europe, Middle East & Africa President of Boston Scientific; Executive: Johnson & Johnson, Biosense Webster |
||
|
|
|
||
|
James Klein Director Former President of Infrastructure and Defense Products, Qorvo, where he was focused on bringing innovative RF technology to the medical testing market |
James J. Barry Director Principal Owner; Convergent Biomedical Group LLC; former President and CEO; InspireMD, Inc.; former SVP of Corporate Technology at Boston Scientific |
|
ANALYST COVERAGE |
Laidlaw & Co (UK) Ltd., Taglich Brothers, Ascendiant Capital Markets, Trickle Research |
| BioSig Forward-Looking Statements: Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements. Data Sources: 2018 MD&D report, Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; CDC Fact Sheet on Atrial Fibrillation; American Heart Association; Ventricular Tachycardia in Medscape, December 2017; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016 , and Biolelectronic Medicine 2019-2029. IDTechEx Research. *As reported in the 09/30/21 form 10Q filed on November 15th, 2021. |
CORPORATE SUMMARY